Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Nock

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Molecular Imaging and Biology|June 12, 2014
GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man studyStephen J Mather, Berthold A Nock, Theodosia Maina, et al.
Molecular Imaging and Biology|March 21, 2018
In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate CancerIngrid L Bakker, Sandra T van Tiel, Joost Haeck, et al.
Pharmaceutics|August 28, 2025
The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [<sup>99m</sup>Tc]Tc-DB8Olga Bragina, Vladimir Chernov, Mariia Larkina, et al.
Global Change Biology|March 5, 2022
Mutually inclusive mechanisms of drought-induced tree mortalityPeter Hajek, Roman M Link, Charles A Nock, et al.
Journal of Medicinal Chemistry|February 23, 2013
Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profilePanteleimon J Marsouvanidis, Berthold A Nock, Bouchra Hajjaj, et al.
Pharmaceutics|October 29, 2025
Phase I Clinical Study with the GRPR-Antagonist [<sup>99m</sup>Tc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?Anna Orlova, Anastasia Rybina, Anna Medvedeva, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2016
68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in OncologySimone U Dalm, Ingrid L Bakker, Erik de Blois, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 29, 2006
[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tateTheodosia Maina, Berthold A Nock, Paul Cordopatis, et al.
Nuclear Medicine and Biology|November 26, 2008
Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptidesWouter A P Breeman, A C Fröberg, E de Blois, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 18, 2016
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsTheodosia Maina, Mark W Konijnenberg, Petra KolencPeitl, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Molecular Imaging and Biology|June 12, 2014
GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man studyStephen J Mather, Berthold A Nock, Theodosia Maina, et al.
Molecular Imaging and Biology|March 21, 2018
In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate CancerIngrid L Bakker, Sandra T van Tiel, Joost Haeck, et al.
Pharmaceutics|August 28, 2025
The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [<sup>99m</sup>Tc]Tc-DB8Olga Bragina, Vladimir Chernov, Mariia Larkina, et al.
Global Change Biology|March 5, 2022
Mutually inclusive mechanisms of drought-induced tree mortalityPeter Hajek, Roman M Link, Charles A Nock, et al.
Journal of Medicinal Chemistry|February 23, 2013
Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profilePanteleimon J Marsouvanidis, Berthold A Nock, Bouchra Hajjaj, et al.
Pharmaceutics|October 29, 2025
Phase I Clinical Study with the GRPR-Antagonist [<sup>99m</sup>Tc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?Anna Orlova, Anastasia Rybina, Anna Medvedeva, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2016
68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in OncologySimone U Dalm, Ingrid L Bakker, Erik de Blois, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 29, 2006
[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tateTheodosia Maina, Berthold A Nock, Paul Cordopatis, et al.
Nuclear Medicine and Biology|November 26, 2008
Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptidesWouter A P Breeman, A C Fröberg, E de Blois, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 18, 2016
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsTheodosia Maina, Mark W Konijnenberg, Petra KolencPeitl, et al.
Pageof 12